AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Keith Speights (AbbVie): AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was part of Abbott) qualify it as a ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

AbbVie provided an optimistic outlook for 2025, with an adjusted EPS guidance range of $12.12 to $12.32 and total net revenues expected to reach $59 billion. The company anticipates significant ...

AbbVie's Q4 EPS of $2.16 beat the forecast by $0.10. Revenue for the quarter was $15.1 billion, exceeding expectations. The stock price increased by 6.82% following the earnings release. Full-year ...

AbbVie cautions that these forward-looking statements ... And so, our BD efforts are focused on building pipeline depth in those areas. Now, I should say if we see an opportunity for ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...